Global  

Oxford COVID-19 vaccine trials produce robust immune response in elderly - FT

WorldNews Monday, 26 October 2020
Oxford COVID-19 vaccine trials produce robust immune response in elderly - FT(Reuters) - Early results from tests for a coronavirus vaccine being developed by the University of Oxford, in collaboration with AstraZeneca Plc, show it produces a robust immune response in elderly people, the group at highest risk,...
0
shares
ShareTweetSavePostSend
 

You Might Like


💡 One News Page Knowledge: Other News Mentions

University of Oxford University of Oxford Collegiate research university in Oxford, England

Gujarat: PM Modi reviews vaccine development at Zydus Cadila facility

Prime Minister Narendra Modi on Saturday began his three-city visit to review coronavirus vaccine development work by going to pharma major Zydus Cadila's..
IndiaTimes

Vaccine tour: PM Modi arrives at SII in Pune to review COVID-19 vaccine development

The Serum Institute of India has partnered with global pharma giant AstraZeneca and Oxford University for the vaccine.
DNA
Government could face ‘tough choices’ over vaccines [Video]

Government could face ‘tough choices’ over vaccines

The Government could face some “tough choices” if the vaccine produced byAstraZeneca and Oxford University is found to be less effective than others, aformer Department of Health director of immunisation has said. Professor DavidSalisbury said ministers would need to think “very carefully” about theirhandling of the vaccine if its efficacy was lower than for other jabs such asthose from Pfizer/BioNTech and Moderna. The AstraZeneca/Oxford vaccine iscurrently being assessed by the Medicines and Healthcare products RegulatoryAgency (MHRA) for use in the UK.Data from two arms of its phase-three trial,announced last week, gave a combined efficacy of 70%.

Credit: PA - Press Association STUDIO    Duration: 00:59Published
AstraZeneca Admits COVID Breakthrough Came From Mistake [Video]

AstraZeneca Admits COVID Breakthrough Came From Mistake

AstraZeneca and the University of Oxford are facing criticism over their COVID-19 vaccine trial results. According to Business Insider the criticism comes after AstraZeneca admitted to a mistake in the vaccine dosage. During the vaccine trial, some patients got two full doses of the vaccine. Others had a half-dose in their first shot, followed by a full dose. On Wednesday, an AstraZeneca executive described the "mistake" as "serendipity.

Credit: Wochit News    Duration: 00:36Published
Dosing Mix-up Raises Questions About New COVID Vaccine [Video]

Dosing Mix-up Raises Questions About New COVID Vaccine

A manufacturing error is raising concerns about a promising COVID-19 vaccine being developed. The vaccine was developed by pharmaceutical company AstraZeneca and the University of Oxford. Less than a week after we learned about it, the developers have admitted to a manufacturing error. The error resulted from two different doses during the recently concluded phase III trial. AstraZeneca and the University of Oxford described the vaccine as being 70% effective.

Credit: Wochit News    Duration: 00:39Published

AstraZeneca British-Swedish pharmaceutical company

India looking to be self-reliant in development, production of vaccine against Covid-19

While at least five pharmaceutical companies of India are engaged in vaccine development, Serum Institute in Pune has been chosen for mass production of..
IndiaTimes
COVID-19 vaccine will be distributed initially in India: CEO Serum Institute of India [Video]

COVID-19 vaccine will be distributed initially in India: CEO Serum Institute of India

COVID-19 vaccine will be distributed initially in India, informed Chief executive officer (CEO) of Serum Institute of India, Adar Poonawalla on November 28. He said, "Vaccine will be distributed initially in India, then we will look at the COVAX countries which are mainly in Africa. The UK and European markets are being taken care of by AstraZeneca and Oxford. Our priority is India and COVAX countries." Earlier in the day, Prime Minister Narendra Modi visited Serum Institute of India in Pune, Maharashtra to and reviewed COVID-19 vaccine development.

Credit: ANI    Duration: 01:25Published

Related videos from verified sources

Oxford Astra Zeneca's vaccine error | What happens to India trials? | Oneindia News [Video]

Oxford Astra Zeneca's vaccine error | What happens to India trials? | Oneindia News

Even as Oxford and Astra Zeneca said that their Covid-19 vaccine had a 90% efficacy, their claims it turned out were based on an accident. Oxford Astrazeneca said that when volunteers were administered..

Credit: Oneindia     Duration: 01:25Published
AstraZeneca COVID-19 vaccine can be 90% effective, results show [Video]

AstraZeneca COVID-19 vaccine can be 90% effective, results show

UK group is the latest drugmaker to unveil positive interim data in a scientific race to curb a global pandemic.

Credit: Al Jazeera STUDIO     Duration: 02:17Published
AstraZeneca, 3rd Major COVID-19 Vaccine, Shown to Be Effective and Cheaper [Video]

AstraZeneca, 3rd Major COVID-19 Vaccine, Shown to Be Effective and Cheaper

AstraZeneca, 3rd Major COVID-19 Vaccine, Shown to Be Effective and Cheaper. On Monday, the drugmaker announced the "exciting results" based on an analysis of trials in the U.K. and Brazil. Because..

Credit: Wibbitz Top Stories     Duration: 01:10Published

Related news from verified sources

Dangers Of Jumping The Gun On A COVID-19 Vaccine – Analysis

Dangers Of Jumping The Gun On A COVID-19 Vaccine – Analysis
By Hannah Clapham* With COVID-19 cases still rising globally, the race is on for a vaccine. Pressures are mounting to get one available for use as soon as...
Eurasia Review Also reported by •Mid-DayNewsySeattlePI.com

Experts: Vaccine Hesitancy Is A Global Threat

Experts: Vaccine Hesitancy Is A Global Threat
Watch VideoExperts say a number of people are skeptical of science-based medical preventions to viruses. It’s called vaccine hesitancy. And it’s especially...
Newsy

Waiting For A Vaccine: Killing For Inequality – OpEd

Waiting For A Vaccine: Killing For Inequality – OpEd
I have been harping on the fact that it is very likely China will be mass producing and distributing a vaccine at least a month, and quite possibly several...
Eurasia Review